Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$32.2 - $42.44 $3.25 Million - $4.28 Million
-100,949 Reduced 65.28%
53,700 $1.73 Million
Q4 2023

Feb 14, 2024

SELL
$31.87 - $40.71 $594,407 - $759,282
-18,651 Reduced 10.76%
154,649 $6.29 Million
Q3 2023

Nov 14, 2023

SELL
$34.17 - $42.98 $24.2 Million - $30.4 Million
-707,368 Reduced 80.32%
173,300 $5.99 Million
Q2 2023

Aug 14, 2023

BUY
$37.4 - $44.52 $6.17 Million - $7.35 Million
165,068 Added 23.07%
880,668 $35.8 Million
Q1 2023

May 15, 2023

BUY
$36.5 - $48.0 $24.1 Million - $31.7 Million
660,500 Added 1198.73%
715,600 $27.7 Million
Q4 2022

Feb 14, 2023

BUY
$37.44 - $46.51 $1.54 Million - $1.91 Million
41,100 Added 293.57%
55,100 $2.45 Million
Q3 2022

Nov 14, 2022

BUY
$42.27 - $57.6 $591,780 - $806,400
14,000 New
14,000 $597,000
Q2 2022

Aug 15, 2022

SELL
$52.3 - $71.59 $26.7 Million - $36.5 Million
-509,800 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$51.32 - $68.5 $13 Million - $17.4 Million
-254,100 Reduced 33.26%
509,800 $31.6 Million
Q4 2021

Feb 14, 2022

BUY
$47.03 - $57.12 $30.4 Million - $36.9 Million
646,000 Added 547.92%
763,900 $42.1 Million
Q3 2021

Nov 15, 2021

SELL
$52.17 - $70.2 $31 Million - $41.7 Million
-594,256 Reduced 83.44%
117,900 $6.2 Million
Q2 2021

Aug 16, 2021

BUY
$68.86 - $83.34 $17 Million - $20.6 Million
246,678 Added 52.99%
712,156 $49.1 Million
Q1 2021

May 17, 2021

BUY
$76.15 - $111.94 $15.7 Million - $23.1 Million
206,278 Added 79.58%
465,478 $35.9 Million
Q4 2020

Feb 16, 2021

BUY
$96.85 - $148.25 $25.1 Million - $38.4 Million
259,200 New
259,200 $25.7 Million

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.87B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.